Analysis Of Clinical Effect And Gene Monitoring Of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor In The Treatment Of Advanced Non-small Cell Lung Cancer

Objective:To investigate the clinical effect and gene monitoring of epidermal growth factor receptor tyrosine kinase inhibitor in the treatment of advanced non-small cell lung cancer.Methods:The clinical data of 50 cases of patients with late non small cell lung cancer in our hospital from January 2014 to January 2017 were retrospectively analyzed,all patients were given gefitinib treatment,the epidermal growth factor receptor phosphorylation and expression of epidermal growth factor receptor,epidermal growth factor receptor tyrosine kinase domain gene mutation were detected.Results:Among the 50 cases of patients,complete remission 0 cases,partial remission 14 cases,stable disease 18 cases,disease progression 18 cases,the objective response rate was 28.0%(14/50).Objective remission rate was significantly correlated with gender and pathological type(p<0.05).The pain,fatigue,loss of appetite,sleep disorders and other symptoms scores,cough,chest pain,arm pain,pain,breathing difficulties and other lung cancer related symptom scores after treatment were significantly lower than before treatment(p<0.05).The improvement rate of anorexia in systemic symptoms of remission patients was significantly higher(p<0.05);the improvement rates of cough,dyspnea,shoulder and arm pain of lung cancer related symptoms were significantly higher than non remission patients(p<0.05).The quality of life(QOL)scores after treatment were significantly higher than before treatment(p<0.05).The improvement rates of quality of life,physical function,role function,cognitive function,social function,comprehensive situation of remission patients were significantly higher than non remission patients(p<0.05).Progression free survival was significantly associated with smoking(p<0.05).The overall survival time was significantly correlated with pathological type and clinical effect(p<0.05).The occurrence of adverse events was 80 cases,the majority of which were rash,diarrhea,the incidence rates were 70.0%,44.0%;followed by nausea,loss of appetite,Bika and ALT increased,oral ulcers,the incidence rates were 10.0%,10.0%,8.0%,8.0%,6.0%;the last was obstructive jaundice,mental declined,the incidence rates were 2.0%.EGFR positive 13 cases,the positive rate was 26.0%.The positive rate of p-EGFR was 24.0%,and the positive rate of p-EGFR of effective patients was significantly higher than ineffective patients(p<0.05).EFGR tyrosine kinase domain gene mutation 16 cases,the positive rate was 32.0%,in which the EFGR tyrosine kinase domain gene mutation rates of women,cancer,smoking,effective disease control patients were significantly higher than male,cancer,smoking,invalid,disease patients(p<0.05),the differences of EFGR tyrosine kinase domain gene mutations rates between different survival progress,overall survival patients were not significant(p<0.05).Conclusion:The clinical efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced non-small cell lung cancer is good,clinical efficacy,survival and EGFR tyrosine kinase domain gene mutations are significantly correlated,so is worthy of the clinical's full attention.